Medivir outlines plans to cut costs, reduce headcount and streamline priorities as the biotech focuses solely on four assets in clinical development.

Bristol-Myers Squibb is teaming up with Compugen to test the latter’s investigational antibody that targets a new checkpoint, PVRIG, in combination with its own antibody Opdivo. Combined inhibition of checkpoint mechanisms, such as PVRIG and TIGIT, is also on the cards for the future.

While Chugai’s satralizumab may not be odds on to win the race for approval, it may beat Alexion’s Soliris on ease of use with a regimen of subcutaneous application once a month versus Soliris’ fortnightly IV.

In a busy week, Carrick Therapeutics has added to its oncology pipeline, as well as bringing in Celgene deal maker George Golumbeski.

Mundipharma widens its biosimilar portfolio by acquiring Cinfa Biotech, and its soon-to-be-launched pegfilgrastim biosimilar.

In an exclusive interview, one of the most direct CEOs in the industry, Regeneron’s Len Schleifer, clarifies his attitude to drug pricing and growing internal innovation.